|
|
||||||||


* Intestinal Disease Research Program, Department of Medicine, and
Department of Molecular Medicine and Pathology, McMaster University, Hamilton, Ontario L8N 3Z5, Canada
| Abstract |
|---|
|
|
|---|
chain expression on Tg T cells. Feeding OVA to SCID-bg mice reconstituted with DO11.10 CD4+CD45RBhigh attenuated the colitis in association with increased TGF-
and IL-10 secretion, and decreased proliferative responses to both OVA and cecal bacteria Ag. OVA feeding also attenuated colitis in SCID-bg mice reconstituted with a mix of BALB/c and DO11.10 CD45RBhigh T cells, suggesting that OVA-induced Treg cells suppressed BALB/c effector cells. The expression of endogenous non-Tg TCR allowed for DO11.10-derived T cells to respond to enteric flora Ag. Furthermore, feeding OVA-induced Treg cells prevented colitis by inducing tolerance in both OVA-reactive and non-OVA-reactive T cells and by inducing Ag-nonspecific Treg cells. Such a mechanism might allow for Ag-nonspecific modulation of intestinal inflammation in inflammatory bowel disease. | Introduction |
|---|
|
|
|---|
The murine colitis model of CD4+CD45RBhigh T cell transfer into SCID mice has provided insight into the effector and regulatory T cell (Treg) mechanisms involved in intestinal inflammation (8, 9). This model requires enteric flora to induce inflammation, yet the specific triggering Ag is not known (1, 10, 11). The requirement for TCR recognition of Ag for Treg cell function is less clear. In a study of Helicobacter infection in the CD45RBhigh colitis model, Treg cell function required previous Ag exposure (12). Other studies suggested that Treg cells can suppress immune pathology triggered by pathogens without previous exposure (10), including Helicobacter infection (13). In addition, in vitro-generated OVA TCR-specific T regulatory 1 (Tr1) cells required OVA to suppress colitis in vivo and did not share Ag specificity with the effector T cells, suggesting Ag-driven bystander suppression (9, 14). Therefore, the requirement for Ag specificity of naturally occurring or in vivo-induced Treg cells in the context of mucosal inflammation remains unclear.
In this study, we used DO11.10 mice as a source of T cells with a defined TCR specificity to follow Ag-specific T cells in the SCID-transfer colitis model. The DO11.10 mouse carries a transgene encoding the TCR specific for chicken OVA323339 peptide on >97% of peripheral T cells (15). OVA-induced oral tolerance in DO11.10 mice involves induction of Treg cells that secrete IL-10 and TGF-
and are associated with the expansion and activation of CD4+CD25+ T cells (16, 17). It remains unclear whether these peripherally induced Treg cells can alter T cell-mediated mucosal inflammation or whether the tolerance is restricted to OVA Ag.
Our results indicate that DO11.10 CD4+CD45RBhigh T cells induced colitis in SCID-bg mice in the absence of OVA, and OVA Tg CD4+CD45RBlow T cells prevented colitis induced by DO11.10-derived CD4+CD45RBhigh without the need for OVA. These findings were associated with the expression of dual TCR, allowing for non-OVA Ag activation of DO11.10 T cells. Furthermore, feeding OVA to SCID-bg mice reconstituted with DO11.10 CD4+CD45RBhigh T cells prevented colitis in association with tolerance against both OVA- and bacterial-derived Ag. More importantly, feeding OVA to mice reconstituted simultaneously with DO11.10- and BALB/c-derived CD4+CD45RBhigh T cells significantly diminished the severity of the colitis. The expression of dual TCR on DO11.10-derived T cells allowed for oral Ag to induce the development of Treg cell function that influence non-OVA specific responses. This is the first demonstration that oral tolerance against a defined Ag can prevent mucosal inflammation associated with T cell stimulation by unrelated Ag(s).
| Materials and Methods |
|---|
|
|
|---|
DO11.10 mice were purchased from Charles River Laboratories (Wilmington, MA) and bred under standard pathogen-free conditions in the central animal facility of McMaster University. Congenic C.B.17/SCID-bg mice and BALB/c mice were obtained from Harlan (Indianapolis, IN). Female mice between 7 and 12 wk of age were used in these studies. All animal experiments were performed in accordance with institutional guidelines as approved by the Animal Care Review Board of McMaster University. Donor and recipient mice in our colony were routinely screened for Helicobacter sp. infection by PCR capable of detecting ribosomal sequences common to all Helicobacter species and were free of infection (data not shown).
Isolation and purification of CD45RBhigh and CD45RBlow CD4+ spleen cells
Spleen cells from DO11.10 or BALB/c mice were used as a source of CD4+ T cells for reconstitution of SCID-bg recipient mice. CD4+ T cell subsets from the spleens were isolated and sorted as described previously (8). Briefly, single-cell suspensions were depleted of B220+, MAC-1+, and CD8+ cells by negative selection using M-450 sheep anti-rat IgG-coated Dynabeads (Dynal Biotech, Oslo, Norway). Purified anti-CD8
, anti-CD11b, anti-MAC1 were obtained from BD PharMingen (Mississauga, Ontario, Canada). CD4+CD45RBhigh and CD4+CD45RBlow fractions were sorted by FACSVantage SE (BD Biosciences, San Jose, CA) under sterile conditions. The purity of each subpopulation was >98%. For preparation of purified transgenic (Tg) CD45RBhigh and CD45RBlow CD4+ T cell subsets, CD4+ T cells derived from naive DO11.10 mice were labeled with FITC-conjugated anti-CD45RB, PE-conjugated anti-KJ1-26 mAbs, and CyChrome-conjugated anti-CD4 mAb. The purity of sorted Tg CD4+ T cell subsets was analyzed before their injection into SCID-bg recipients and was >98%.
Reconstitution of SCID-bg mice with T cell subsets and OVA feeding
DO11.10-derived CD4+CD45RBhigh and CD4+CD45RBlow T cells were washed and resuspended at 2 x 106 cells/ml in sterile PBS. Seven- to 12 wk-old SCID-bg mice each received either CD4+CD45RBhigh T cells (4 x 105 cells i.p.) alone or combined with CD45RBlowCD4+ T cells (2 x 105). In some experiments, CD4+ T cells subsets derived from BALB/c and DO11.10 mice were mixed and injected into SCID-bg mice. Mice were monitored twice weekly for change in body weight, evidence for soft stool, or diarrhea, bloody diarrhea, and rectal prolapse. Mice were sacrificed when they exhibited two or more of the following signs: 1) a loss of >15% of their original body weight, 2) the development of a large (>3-mm) rectal prolapse, or 3) extensive diarrhea or bloody stools. Some of the recipient mice were fed OVA (1 mg/ml; Sigma-Aldrich, St. Louis, MO) or PBS in the drinking water. This regimen of OVA feeding was previously shown to induce oral tolerance with suppression of OVA responses in DO11.10 mice (18). The average water consumption is
45 ml/mouse/day. The drinking water was changed every 3 days.
Histological examination
Recipient SCID-bg mice were sacrificed 812 wk after reconstitution. The colon was opened longitudinally and separated into ascending, transverse, and descending colon and cecum. Tissues were fixed in 10% buffered formalin, sectioned, and stained with H&E. Each segment was analyzed for the severity of intestinal inflammation and graded on a scale from 0 (no change) to 4 (most severe), as described previously (19). The scores at each segment were combined to provide an overall score of inflammation with a maximum score of 16.
Phenotypic analysis by flow cytometry
Preparation for flow cytometry analysis involved suspending 5 x 105 mononuclear cells (MNC) isolated from spleen or mesenteric lymph node (MLN) in PBS/0.2% w/v BSA supplemented with 0.1% w/v sodium azide. Cells were then incubated with relevant mAb for 30 min at 4°C and washed. Three-color flow cytometry acquisition was performed on FACScan (BD Biosciences). The following reagents and mAbs were obtained from BD PharMingen: FITC-conjugated hamster anti-CD3
(145-2C-11), PE- and CyChrome-conjugated anti-CD4 mAb (L3T4), PE-conjugated CD25 (IL-2R
-chain, p55), PE-conjugated anti-V
2 TCR (B20.1), and FITC- and PE-conjugated rat IgG2b. FITC- and PE-conjugated mAb specific for DO11.10 Tg TCR clonotype (clone KJ1-26) were purchased from Caltag Laboratories (Burlingame, CA). A total of 5 x 105 events gated on lymphocytes was collected by FACScan using the CellQuest software, and the data was analyzed by WinList version 5.0 (Verity Software House, Topsham, ME).
Preparation of cecal bacterial Ag (CBA)
CBA was prepared as previously described (5). The cecum removed from BALB/c or DO11.10 mice was placed in PBS and mixed on a vortex. After removing residual tissue, the suspension was sonicated 10 times for 30 s on ice. The suspension was then centrifuged at 10,000 x g for 10 min. The supernatant was collected, sterile filtered through a 0.22-µm syringe filter, and stored at -20°C. The protein concentration in the supernatants was typically 1.53.0 mg/ml.
Proliferation assay
APCs were prepared from BALB/c spleen cells and pulsed with OVA (1 mg/ml) or CBA (200 µg/ml) in six-well plates. After incubation for 18 h, the cells were washed and irradiated (3000 rad). Proliferation assays were performed as previously described (20). Briefly, 100 µl of 5 x 106 lymphoid cells per milliliter was added to 96-well flat-bottom tissue culture plates along with Ag-pulsed APC (5 x 106/well) in DMEM supplemented with 10% heat-inactivated FBS, 2 mM-L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 50 µM 2-ME (Sigma-Aldrich). Plate-bound anti-CD3 (5 µg/ml) or Con A (1 µg/ml) was used as positive control. Each treatment was set in triplicate and maintained for 5 days at 37°C in 5% CO2. Cell cultures were pulsed with 1 µCi of [3H]thymidine for the last 16 h, and proliferation responses were determined by measuring [3H]thymidine incorporation.
Cytokine measurement
Cytokine production was measured in cell culture supernatants. Supernatants were stored at -20°C until analysis by ELISA specific for IL-2, TNF-
, and IL-10 performed according to manufacturers specification (R&D Systems, Minneapolis, MN). TGF-
concentrations were determined using the commercially available TGF-
Quantikine kit (R&D Systems). Data were analyzed against the linear portion of the generated standard curve using calibrated standards provided by the manufacturers.
Statistical analysis
Data were expressed as mean ± SEM. Statistical analysis was performed using the two-tailed Students t test for independent samples. Mann-Whitney was used for nonparametric data. One-way ANOVA was used for time course data. The differences between the mean of two groups were considered significant when the value of p < 0.05.
| Results |
|---|
|
|
|---|
A variable proportion of DO11.10 T cells in peripheral lymphoid tissue express a second TCR due to incomplete allelic exclusion at the TCR
locus (i.e., Tg
-chain plus non-Tg
-chain) (21). A significant proportion of DO11.10 lamina propria lymphocytes express the activated/memory-like T cell phenotype, suggesting that enteric bacterial activated these Tg T cells through a nonclonotypic TCR (21, 22). Single- and dual-TCR-expressing T cells can be distinguished by flow cytometry analysis of the relative expression of CD3 vs the clonotypic marker of the Tg TCR, KJ1-26, based on the fixed stoichiometry of expression of total TCR to CD3 (21, 23). A typical distribution pattern (Fig. 1A) of the expression of KJ1-26 vs CD3 fluorescence on DO11.10-derived splenocytes showed that
12.2 ± 2.8% of CD3+KJ1-26+ cells expressed an intermediate intensity of KJ1-26, i.e., a <1:1 ratio with CD3. V
2 represents a non-Tg V
chain that is rarely expressed by cells with the high KJ1-26:CD3 ratio, but is found on cells with a lower KJ1-26:CD3 ratio (Fig. 1A), indicating that the T cells with lower KJ1-26:CD3 ratio express both the clonotypic TCR KJ1-26 and a second TCR. V
2 is just one representative example of non-Tg TCR V
chain rearrangement (21).
|
2 plus another V
chain) from BALB/c mice were CD4+CD45RBlow T cells, whereas only 18.1% of single V
2-expressing T cells expressed CD4+CD45RBlow. This suggests that, although only a small portion of Tg T cells express a second TCR with endogenous V
chain, a majority of those dual-TCR-expressing cells are represented in the T cell subsets expressing phenotypic markers of activation/memory and Treg cells. SCID-bg mice reconstituted with OVA-specific TCR Tg (DO11.10) CD45RBhighCD4+ T cells developed colitis in the absence of OVA Ag
Given that DO11.10 T cells can express nonclonotypic TCR, one would predict that CD4+CD45RBhigh T cells could induce colitis on transfer into SCID mice in the absence of OVA. However, the only previous report used preactivated DO11.10 CD4 T cells to induce colitis on transfer into SCID mice (11). Therefore, to determine whether nonactivated CD4+CD45RBhigh T cells from DO11.10 mice were able to induce colitis in the absence of OVA, we transferred CD4+CD45RBhigh T cells from OVA naive DO11.10 mice into SCID-bg mice. These mice developed weight loss starting at
45 wk after cell transfer (Fig. 2). Diarrhea and rectal prolapse developed by 810 wk. The time course and severity of the colitis was similar to that seen after BALB/c-derived CD4+CD45RBhigh T cells were transferred into SCID-bg mice (data not shown). Histological examination of SCID-bg mice reconstituted with DO11.10 CD4+CD45RBhigh T cells showed a transmural inflammation that was most severe in the transverse colon (Fig. 3A) and was similar to conventional BALB/c into SCID transfer colitis (19).
|
|
To determine whether DO11.10 CD45RBlowCD4+ T cells could control the colitis induced by DO11.10 CD45RBhigh T cells in the absence of OVA stimulation, 2 x 105 DO11.10 CD45RBlow T cells were injected into SCID-bg mice together with 4 x 105 DO11.10 CD45RBhigh T cells. In contrast to mice receiving DO11.10 CD45RBhigh T cells alone, animals reconstituted with both T cell subsets failed to lose weight (Fig. 2) and failed to develop colonic inflammation (Fig. 3B). These data indicate that DO11.10 CD4+CD45RBlow T cells functioned as Treg cells in the absence of Ag specifically recognized by the Tg TCR.
Phenotype of DO11.10-derived CD4+ T cell subsets after transfer into SCID-bg mice
Previously, studies showed that BALB/c-derived CD4+ T cell subsets repopulated the peripheral lymphoid tissues of SCID mice (8, 11). Our data showed that DO11.10 T cells were identifiable in SCID-bg recipients (Table I). Therefore, DO11.10 Tg CD4+ T cell subsets were able to reconstitute SCID-Bg mice even in the absence of the specific Ag OVA. The number of CD4+ T cells in spleen and MLN of SCID-bg mice reconstituted with Tg CD45RBhigh subsets was higher than that found in SCID-bg mice reconstituted with both CD45RBhigh and CD45RBlow T cell subsets (Table I).
|
|
2 chain. In the donor DO11.10 mice, only 4.6 ± 0.8% (n = 4) of the splenic CD4+ T cells (KJ1-26+) expressed a second non-Tg V
2, whereas there was a 2- to 4-fold increase in cells expressing non-Tg V
TCR chain in the spleen from both CD45RBhigh alone or combined CD45RBhigh and RBlow recipients (Fig. 4 and Table I). Furthermore, analysis of the expression of the Tg V
8 TCR chain as detected by F23.1 mAb (specific for V
8.1, -8.2, -8.3) on CD4+ T cells, showed that colitic mice exhibited a 2-fold increase in non-Tg KJ1-26-CD4+ T cells, suggesting that a higher percentage of CD4+ T cells expressed endogenous non-Tg
-chains as compared with SCID-bg mice reconstituted with both DO11.10 CD45RBlow and RBhigh T cells (Fig. 4B). These data indicate that the emergence of a second non-Tg TCR could permit effector T cells to respond to non-OVA Ag such as those present in the gut flora. Oral administration of OVA attenuated the colitis in SCID-bg mice reconstituted with OVA-specific TCR DO11.10 CD45RBhighCD4+ T cells
Feeding OVA to DO11.10 mice induced oral tolerance to OVA Ag via the induction of regulatory-type T cells (16). To determine whether feeding OVA would prevent T cell-mediated colitis, we fed OVA to SCID-bg mice reconstituted with DO11.10 CD4+CD45RBhigh T cells. SCID-bg recipients were allowed to drink water containing OVA (1 mg/ml) starting 1 day after reconstitution. The DO11.10 CD45RBhigh-transferred SCID-bg mice fed OVA were significantly protected from the development of weight loss (Fig. 5A), and this was associated with a significant reduction in the severity of colitis (Figs. 5B, and 3, C and D). At the time of sacrifice, the mean histological colitis score was 8.56 ± 0.8 for PBS-fed SCID-bg mice reconstituted with DO11.10-derived CD4+CD45RBhigh T cells, whereas the average score for OVA-fed recipients was 4.93 ± 0.76 (p < 0.002). OVA feeding did not induce any difference in weight loss or intestinal inflammation in the mice reconstituted with both DO11.10 CD4+CD45RBhigh and CD4+CD45RBlow T cells (Fig. 5). Feeding OVA did not alter the colitis in SCID-bg mice reconstituted with BALB/c-derived CD4+CD45RBhigh T cells (data not shown).
|
|
To investigate whether feeding OVA to CD45RBhigh-reconstituted SCID-bg mice led to Ag-specific tolerance, we measured in vitro proliferation and cytokine responses to both OVA and Ag derived from CBA. MNC from spleen were isolated from OVA- and PBS-fed SCID-bg recipients of DO11.10-derived CD4+CD45RBhigh T cells. These cells were restimulated in vitro with CBA- or OVA-pulsed APC. There was significant proliferation in the spleen of the PBS-fed SCID-bg mice receiving DO11.10 CD4+CD45RBhigh T cells in response to both OVA and CBA. In contrast, OVA feeding significantly reduced the proliferative response to both CBA and OVA (Fig. 6A). Cytokine production of MNC from OVA-fed and PBS-fed SCID-bg recipient mice was measured in spleen cells restimulated with CBA and OVA-pulsed APC in vitro; IL-2, TNF-
, TGF-
, and IL-10 levels were measured by ELISA in supernatants collected 4 days after in vitro stimulation (Fig. 6B). OVA-fed mice had a significant decrease in IL-2 and TNF-
responses to both CBA and OVA stimulation. In contrast, production of the regulatory cytokine TGF-
in response to both CBA and OVA stimulation was significantly increased. IL-10 production was undetectable in MNC from both PBS- and OVA-fed SCID-bg mice receiving CD4+CD45RBhigh T cells, in response to CBA- and OVA-pulsed APC. Therefore, OVA feeding induced tolerance to both the specific Ag OVA and to the unrelated Ags in gut flora. The effect of OVA feeding on proliferative and cytokine responses in these reconstituted mice may be due to induction of anergy of T cells expressing dual TCRs or due to the induction of Th3-type Treg cells that nonspecifically down-regulate all T cell responses.
|
To further examine whether feeding OVA would prevent non-OVA Tg T cell-mediated colitis, we transferred equal numbers of CD4+CD45RBhigh T cells from BALB/c and DO11.10 mice (1:1 ratio; total of 4 x 105 per mouse) to SCID-bg mice. Half of the recipients were fed OVA Ag (or PBS as control). The time course of disease onset and the intestinal inflammation induced by mixed CD4+CD45RBhigh T cells was similar to that seen in mice receiving T cells derived from either BALB/c or DO11.10 mice alone. OVA feeding mice reconstituted with the combination of both BALB/c and DO11.10 CD45RBhigh T cells significantly prevented the weight loss (Fig. 7A) and the severity of colonic inflammation (Fig. 3, E and F). The overall inflammation score for OVA-fed group was 4.9 ± 1.1 compared with 10.1 ± 0.9 in the non-OVA-fed group (Fig. 7B; p < 0.01).
|
|
| Discussion |
|---|
|
|
|---|
This study is the first to demonstrate that naive nonactivated DO11.10 CD45RBhighCD4+ T cells can cause colitis in SCID-bg mice in the absence of the specific Ag, OVA. This finding implies that the effector T cells were stimulated through a nonclonotypic TCR. Because CD45RBhigh induction of colitis is dependent on the presence of gut flora (1, 11), it is reasonable to speculate that gut flora-derived Ag stimulated the relevant effector T cells through non-Tg TCR. This conclusion is supported by previous studies showing that naive CD4 T cells (presumably all are CD4+CD45RBhigh) from DO11.10 mice backcrossed onto RAG-deficient background failed to induce colitis (6), and that enteric bacteria can activate OVA-specific TCR Tg T cells in DO11.10 mice through a nonclonotypic TCR (21, 24). Indeed, we showed that the majority of OVA Tg CD4+CD45RBhigh T cells transferred into SCID-bg mice become activated and replace their CD45RBhigh phenotype with expression of the activation/memory phenotype, CD45RBlow, and express non-Tg V
chains. Therefore, these T cells express more than one TCR, i.e., one clonotypic TCR with both the Tg V
13.1 and V
8.2 chains (KJ1-26+) and a second TCR with the Tg V
8.2 chain associated with a non-Tg V
chain.
The ability of T cells to express a dual TCR is not limited to these Tg mice in that T cells expressing dual TCR have been described in non-Tg rodents as well as in humans (23, 25). Dual-TCR-bearing T cells are generated in the thymus (26, 27, 28) and may contribute to the induction of autoimmunity (29, 30) and to the generation of TCR repertoire diversity (31). In addition, there are case descriptions of clonal expansion of dual-TCR-expressing T cells in patients with IBD, HIV infection, and T cell malignancies (32, 33). In spontaneous murine models of colitis in TCR Tg lymphopenic mice, T cells with dual
-chains paired with Tg-encoded
-chain were increased in the inflamed colons but not on noninflamed colon, suggesting polyclonal T cell activation (34). Thus, dual-TCR T cells may have an important role in the pathogenesis of IBD through immune recognition of cross-reactive and triggering Ags such as found in normal gut flora Ag. The question of why these cells respond to normal enteric flora in mice remains to be addressed.
The data presented in this report also showed that cotransfer of DO11.10 CD45RBlow T cells into SCID-bg mice prevented colitis-induced DO11.10-derived CD4+CD45RBhigh T cells in the absence of the specific Ag, OVA. Therefore, Treg cells functioned independent of cognate Ag and influenced T cells that do not share Ag specificity. This finding raises the possibility that Treg T cells can also be activated through nonclonotypic TCR. The significant proportion of OVA Tg CD4+CD45RBlow T cells that express a second TCR chain, together with the finding that >50% of dual-TCR-bearing T cells express CD4+CD45RBlow phenotype in BALB/c mice, suggests that naturally occurring Treg cells maintain an extended TCR repertoire and are readily responsive to a wide range of self or nonself Ag. We cannot exclude the possibility of that Treg cell activation can occur through Ag-nonspecific polyclonal pathways or even via TCR-independent activation pathways such as LPS-Toll-like receptors interactions (35).
Dual-TCR expression on naturally occurring Treg cells might reflect the importance of endogenous TCR
-chains in the development of immune tolerance. This would help explain the development of colitis in TCR
-chain-deficient mice (36, 37), as well as in other TCR Tg mice backcrossed onto RAG-2-deficient mice (34, 38, 39). Loss of the TCR
-chain was associated with the concomitant loss of suppressor activity of Ag-specific T suppressor cell lines (40).
The presence of T cells expressing two TCRs sets up a scenario where a specific Ag, e.g., OVA, influences T cell responses to non-OVA Ag. This is supported by the finding that feeding low-dose OVA to SCID-bg mice transferred with DO11.10 CD45RBhigh T cells attenuated the development of colitis. This finding is analogous to the results described by Fossati et al. (41) who showed that triggering a second TCR on diabetogenic T cells prevented the induction of diabetes. OVA feeding was not associated with deletion of Tg T cells but was associated with suppression of T cells responses, i.e., a decrease in proliferation and proinflammatory cytokine, and increase in suppressive cytokines such as TGF-
, responses to both OVA and CBA stimulation in vitro. Therefore, OVA feeding not only induced tolerance in OVA-specific TCR-carrying T cells, but also tolerized responses to unrelated gut flora Ag. In addition, the finding that feeding OVA diminished colitis in mice reconstituted with both DO11.10- and BALB/c-derived CD45RBhigh T cells indicates that OVA feeding induced a Treg cell that influenced both Tg and BALB/c effector T cells. In support of our argument, total CD4+KJ1-26+ T cells numbers recovered from MLN and spleen from both OVA-fed and PBS-fed recipients (BALB/c plus DO11.10 CD4+CD45RBhigh) were similar, excluding the possibility of Ag-specific deletion. Therefore, feeding Ag induced cytokines associated with previously described Treg cells. These findings also suggest that Treg cells are involved in suppressing effector T cells that do not share Ag specificity.
The studies described in this report demonstrate that adoptive transfer of DO11.10 T cells into SCID-bg mice allowed us to follow Ag-specific T cell responses during the induction and regulation of colitis. Others using DO11.10-derived T cells showed that in vitro-generated DO11.10 Tr1 cells inhibited CD45RBhigh-induced colitis but only when recipients were fed OVA (14), suggesting that the suppressive function of Tr1 clones inhibited the function of effector T cells responding to unrelated Ags. In contrast, OVA-specific Tr1 clones failed to prevent spontaneous autoimmune encephalomyelitis in myelin basic protein-specific Tg mice with a disrupted RAG-1 gene, even in the presence of OVA Ag (39). The reasons for this discrepancy are not clear but may reflect the fact that these Tr1 clones were preactivated in vitro by OVA peptide, which may eliminate T cells expressing non-Tg TCR, thereby limiting their TCR repertoire diversity.
In conclusion, we demonstrated that the OVA TCR Tg CD4+ T cells, with their ability to express a second TCR, can act as both effector and Treg cells in the initiation and modulation of T cell-mediated colitis independent of cognate Ag. In addition, low-dose OVA feeding induced T cell hyporesponsiveness to both OVA and CBA and attenuated the mucosal inflammation induced by OVA-specific TCR Tg T cells. More importantly, OVA-induced tolerance suppressed BALB/c CD45RBhigh T cell-induced colitis. The fact that regulatory function can be induced directly from naive T cells by a model Ag unrelated to the Ag driving the colitis opens the possibility of new therapeutic approaches in this disease.
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Kenneth Croitoru, Intestinal Diseases Research Program, Division of Gastroenterology, McMaster University, 1200 Main Street West, Room 4W8, Hamilton, Ontario L8N 3Z5, Canada. E-mail address: Croitoru{at}mcmaster.ca ![]()
3 Abbreviations used in this paper: IBD, inflammatory bowel disease; Treg cell, T regulatory cell; Tr1, T regulatory 1; Tg, transgenic; MNC, mononuclear cell; MLN, mesenteric lymph node; CBA, cecal bacterial Ag; RAG, recombination-activating gene. ![]()
Received for publication August 4, 2003. Accepted for publication November 24, 2003.
| References |
|---|
|
|
|---|
, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157:1261.[Abstract]
chains: dual receptor T cells. Science 262:422.
chains: implications for the mechanism of allelic exclusion. J. Exp. Med. 181:1587.
chain genes maximize the production of useful thymocytes. J. Exp. Med. 178:615.
and
T cell receptor alleles. Cell 69:529.[Medline]
chain T cells in autoimmunity. J. Exp. Med. 182:953.
T cells in blood of patients with inflammatory bowel diseases. J. Immunol. 156:2331.[Abstract]
-chain polymorphisms. Gastroenterology 99:288.[Medline]
mutant mice requires a T helper 2 environment. Gastroenterology 119:983.[Medline]
chain plays a critical role in antigen-specific suppressor cell function. Proc. Natl. Acad. Sci. USA 88:8700.This article has been cited by other articles:
![]() |
T L Freitag, S Rietdijk, Y Junker, Y Popov, A K Bhan, C P Kelly, C Terhorst, and D Schuppan Gliadin-primed CD4+CD45RBlowCD25- T cells drive gluten-dependent small intestinal damage after adoptive transfer into lymphopenic mice Gut, December 1, 2009; 58(12): 1597 - 1605. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Heriazon, P. Zhou, R. Borojevic, K. Foerster, C. J. Streutker, T. Ng, and K. Croitoru Regulatory T Cells Modulate Staphylococcal Enterotoxin B-Induced Effector T-Cell Activation and Acceleration of Colitis Infect. Immun., February 1, 2009; 77(2): 707 - 713. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sharma, A. C.-Y. Ju, J. T. Kung, S. M. Fu, and S.-T. Ju Rapid and Selective Expansion of Nonclonotypic T Cells in Regulatory T Cell-Deficient, Foreign Antigen-Specific TCR-Transgenic Scurfy Mice: Antigen-Dependent Expansion and TCR Analysis J. Immunol., November 15, 2008; 181(10): 6934 - 6941. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ishimaru, A. Yamada, M. Kohashi, R. Arakaki, T. Takahashi, K. Izumi, and Y. Hayashi Development of Inflammatory Bowel Disease in Long-Evans Cinnamon Rats Based on CD4+CD25+Foxp3+ Regulatory T Cell Dysfunction J. Immunol., May 15, 2008; 180(10): 6997 - 7008. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Kapp, K. Honjo, L. M. Kapp, K. Goldsmith, and R. P. Bucy Antigen, in the Presence of TGF-beta, Induces Up-Regulation of FoxP3gfp+ in CD4+ TCR Transgenic T Cells That Mediate Linked Suppression of CD8+ T Cell Responses J. Immunol., August 15, 2007; 179(4): 2105 - 2114. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M Strutt, J. Uzonna, K. K McKinstry, and P. A Bretscher Activation of thymic T cells by MHC alloantigen requires syngeneic, activated CD4+ T cells and B cells as APC Int. Immunol., May 1, 2006; 18(5): 719 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Samy, L. A. Parker, C. P. Sharp, and K. S.K. Tung Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node J. Exp. Med., September 19, 2005; 202(6): 771 - 781. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Safadi, C. E. Alvarez, M. Ohta, J. Brimnes, T. Kraus, W. Mehal, J. Bromberg, L. Mayer, and S. L. Friedman Enhanced Oral Tolerance in Transgenic Mice with Hepatocyte Secretion of IL-10 J. Immunol., September 15, 2005; 175(6): 3577 - 3583. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fahlen, S. Read, L. Gorelik, S. D. Hurst, R. L. Coffman, R. A. Flavell, and F. Powrie T cells that cannot respond to TGF-{beta} escape control by CD4+CD25+ regulatory T cells J. Exp. Med., March 7, 2005; 201(5): 737 - 746. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |